Search

Your search keyword '"Reiner, Z"' showing total 385 results

Search Constraints

Start Over You searched for: Author "Reiner, Z" Remove constraint Author: "Reiner, Z"
385 results on '"Reiner, Z"'

Search Results

1. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

4. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

5. POSITIVE TRENDS IN AWARENESS OF HARMFUL EFFETCS OF HIGH SALT INTAKE - 10 YEARS CROATIAN ACTION ON SALT AND HEALTH (CRASH). DATA FROM 2008 AND 2017 WORLD HYPERTENSION DAYS

7. The time is now: Achieving FH paediatric screening across Europe - The Prague Declaration

8. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

9. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

10. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

11. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

12. Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

13. Naturally Occurring Bioactives as Antivirals: Emphasis on Coronavirus Infection

15. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

18. ESC Core Curriculum for the General Cardiologist (2013)

19. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry

20. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

21. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

22. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

23. Third universal definition of myocardial infarction

24. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

26. 4115Effect of alirocumab on recurrent cardiovascular events after acute coronary syndrome, according to the intensity of background statin treatment

27. 1443Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials

28. Canopy Transpiration in a Chronosequence of Central Siberian Pine Forests

29. Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score

30. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS)

31. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an 'FCS score'

32. Characterisation of patients with familial chylomicronaemia syndrome (FCS) and multifactorial chylomicronaemia syndrome (MCS): Establishment of an FCS clinical diagnostic score

34. Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

35. Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel

36. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

37. [InlineMediaObject not available: see fulltext.]European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) - The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of Nine Societies and by Invited Experts)

38. Erratum: 'European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)' the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)

40. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular disease (Part III)

41. Effect of L-Dopa on Growth Hormone, Glucose, Insulin, and Cortisol Response in Obese Subjects

42. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

43. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts)

45. 2012 Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation [Actualización detallada de las guías de la ESC para el manejo de la fibrilación auricular de 2012]

46. ESC core curriculum for the general cardiologist (2013)

47. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association

48. Guidelines for the diagnosis and treatment of pulmonary hypertension Orientações para o diagnóstico e tratamento da hipertensão pulmonar

49. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

50. Myocardial revascularization

Catalog

Books, media, physical & digital resources